Cepacaine antibacterial and anaesthetic mouthwash

Cepacaine is a specialized therapeutic oral solution formulated to provide temporary relief from pain and discomfort caused by sore throats, mouth infections, and dental procedures. It is particularly well-known in the Australasian market as a dual-action treatment containing both an antibacterial agent (Cetylpyridinium chloride) and an anaesthetic agent (Benzocaine) to provide rapid numbing and infection control.

The brand has a long history within the consumer healthcare sector, having been part of various global pharmaceutical portfolios. Today, Cepacaine is a core brand under the iNova Pharmaceuticals umbrella. iNova is a multinational pharmaceutical company that focuses on acquiring and maximizing the potential of trusted consumer health brands. While the product is marketed across several regions, its primary manufacturing and distribution hubs are located in Australia, ensuring compliance with rigorous pharmaceutical standards.

Ownership of Cepacaine shifted significantly in recent years. After being part of larger entities like Valeant (now Bausch Health), iNova Pharmaceuticals became an independent entity owned by investment groups. Following a major acquisition in late 2022 and early 2023, the ultimate parent company of iNova—and consequently Cepacaine—became TPG Capital, a global private equity firm headquartered in the United States.